Gynecomastia denials in California external review
In the California DMHC record, independent physician reviewers decided 59 published external-review cases involving gynecomastiaand overturned the plan’s denial in 30.5%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for gynecomastia
| Category | Decisions | Overturned |
|---|---|---|
| Mastectomy | 10 | 40% |
| Bilateral Mastectomy | 9 | 11.1% |
| Liposuction | 7 | 42.9% |
| Breast Reduction Surgery | 3 | 0% |
| Bilateral Reduction Mammoplasty | 3 | 33.3% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 55 | 27.3% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 4 | 75% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for bilateral mastectomy and liposuction procedure (CPT 19300 and 15877). Arya and colleagues state that, “True gynecomastia refers to enlarged glandular tissue rather than deposition of fat tissue. Enlargement of breast due to deposition of fat in the breast area is known as pseudogynecomastia.” The authors noted that, “The aims of surgery are: (a) To eliminate painful breast tissue. (b) To restore the patient’s chest to acceptable cosmetic shape. The most commonly used technique is subcutaneous mastectomy that involves direct resection of the glandular tissue using a peri-areolar or trans-areolar approach, with or without liposuction.” Per the American Society of Plastic Surgeons (ASPS), the requested bilateral mastectomy and liposuction procedure are not medically necessary.
Nature of Statutory Criteria/Case Summary: The patient requested reimbursement for a mastectomy. Gynecomastia is the presence of an abnormal proliferation of breast tissue that accounts for up to 65% of male breast disorders. Gynecomastia has a broad range of causes that are classified as either physiological or pathological, although in many cases, no specific cause can be found. In a study, the authors reported that guidelines for gynecomastia state that, “gynecomastia (GM) is a benign proliferation of the glandular tissue of the breast in men. It is a frequent condition with a reported prevalence of 32 to 65%, depending on the age and the criteria used for definition.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for bilateral mastectomy. According to the American Society of Plastic Surgeons (ASPS), “gynecomastia is defined as the presence of an abnormal proliferation of breast tissue in males.” However, the ASPS noted that, “in pseudogynecomastia, the breast enlargement is secondary to fat accumulation; and both glandular and fat tissue are present in mixed gynecomastia. Gynecomastia is different from pseudogynecomastia, which is an increase in subareolar fat often related to obesity.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for mastectomy. Gynecomastia is defined as the presence of an abnormal proliferation of breast tissue in males with a broad range of causes that are classified as either physiological or pathological, although in many cases no specific cause can be found. In true gynecomastia, the breast enlargement is due to glandular breast tissue while in pseudogynecomastia, the breast enlargement is secondary to fat accumulation. Both glandular and fat tissue are present in mixed gynecomastia. Gynecomastia is to be differentiated from pseudogynecomastia, an increase in subareolar fat often related to obesity. True gynecomastia has a palpable firm disc of tissue under the nipple areolar complex.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving gynecomastia, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY